Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

5.145 +0.025 (+0.49%)
Streaming Delayed Price Updated: 3:34 PM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sionna Therapeutics, Inc. - Common Stock

News headline image
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗
This company has had plenty of setbacks in recent years, but it generally bounces back. 
Via The Motley Fool
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
They could both outperform the market over the medium term, but one appears to have a clear edge. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Don't bet against Vertex Pharmaceuticals in cystic fibrosis. 
Via The Motley Fool
Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar ↗
Via Stocktwits
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)... 
Via Benzinga
News headline image
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path ↗
Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue... 
Via MarketBeat
News headline image
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗
This risk is weighing on the stock. 
Via The Motley Fool
News headline image
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch ↗
This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story ↗
This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway. 
Via The Motley Fool
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing. 
Via The Motley Fool
News headline image
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares ↗
After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million ↗
This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial ↗
Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
AI Mobility Provider, Steel Veteran Made Trading Debuts ↗
AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology, and Singapore-based med-tech Basel Medical all made their public debuts... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
News headline image
Sionna Therapeutics, Titan America Made Public Debut ↗
Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a modest opening, just slightly higher than its initial... 
Via Talk Markets
Topics Stocks / Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.